343 related articles for article (PubMed ID: 21673796)
1. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
Neff CP; Kurisu T; Ndolo T; Fox K; Akkina R
PLoS One; 2011; 6(6):e20209. PubMed ID: 21673796
[TBL] [Abstract][Full Text] [Related]
2. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
Neff CP; Ndolo T; Tandon A; Habu Y; Akkina R
PLoS One; 2010 Dec; 5(12):e15257. PubMed ID: 21203568
[TBL] [Abstract][Full Text] [Related]
3. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.
Barouch DH; Klasse PJ; Dufour J; Veazey RS; Moore JP
Proc Natl Acad Sci U S A; 2012 May; 109(22):8694-8. PubMed ID: 22586094
[TBL] [Abstract][Full Text] [Related]
4. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.
Veselinovic M; Neff CP; Mulder LR; Akkina R
Virology; 2012 Oct; 432(2):505-10. PubMed ID: 22832125
[TBL] [Abstract][Full Text] [Related]
5. Role of Semen on Vaginal HIV-1 Transmission and Maraviroc Protection.
Council OD; Swanson MD; Spagnuolo RA; Wahl A; Garcia JV
Antimicrob Agents Chemother; 2015 Dec; 59(12):7847-51. PubMed ID: 26392489
[TBL] [Abstract][Full Text] [Related]
6. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.
Malcolm RK; Veazey RS; Geer L; Lowry D; Fetherston SM; Murphy DJ; Boyd P; Major I; Shattock RJ; Klasse PJ; Doyle LA; Rasmussen KK; Goldman L; Ketas TJ; Moore JP
Antimicrob Agents Chemother; 2012 May; 56(5):2251-8. PubMed ID: 22330914
[TBL] [Abstract][Full Text] [Related]
7. Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV.
Ball C; Woodrow KA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4855-65. PubMed ID: 24913168
[TBL] [Abstract][Full Text] [Related]
8. Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.
Forbes CJ; McCoy CF; Murphy DJ; Woolfson AD; Moore JP; Evans A; Shattock RJ; Malcolm RK
J Pharm Sci; 2014 May; 103(5):1422-32. PubMed ID: 24585370
[TBL] [Abstract][Full Text] [Related]
9. Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice.
Berges BK; Akkina SR; Folkvord JM; Connick E; Akkina R
Virology; 2008 Apr; 373(2):342-51. PubMed ID: 18207484
[TBL] [Abstract][Full Text] [Related]
10. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.
Forbes CJ; Lowry D; Geer L; Veazey RS; Shattock RJ; Klasse PJ; Mitchnick M; Goldman L; Doyle LA; Muldoon BC; Woolfson AD; Moore JP; Malcolm RK
J Control Release; 2011 Dec; 156(2):161-9. PubMed ID: 21864598
[TBL] [Abstract][Full Text] [Related]
11. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Veselinovic M; Yang KH; LeCureux J; Sykes C; Remling-Mulder L; Kashuba ADM; Akkina R
Virology; 2014 Sep; 464-465():253-263. PubMed ID: 25105490
[TBL] [Abstract][Full Text] [Related]
12. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.
Veazey RS; Ketas TJ; Dufour J; Moroney-Rasmussen T; Green LC; Klasse PJ; Moore JP
J Infect Dis; 2010 Sep; 202(5):739-44. PubMed ID: 20629537
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
Fox J; Tiraboschi JM; Herrera C; Else L; Egan D; Dickinson L; Jackson A; Olejniczak N; Back D; Khoo S; Shattock R; Boffito M
J Acquir Immune Defic Syndr; 2016 Nov; 73(3):252-257. PubMed ID: 27727157
[TBL] [Abstract][Full Text] [Related]
14. Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
Sepúlveda-Crespo D; Sánchez-Rodríguez J; Serramía MJ; Gómez R; De La Mata FJ; Jiménez JL; Muñoz-Fernández MÁ
Nanomedicine (Lond); 2015; 10(6):899-914. PubMed ID: 25867856
[TBL] [Abstract][Full Text] [Related]
15. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
Kang Y; Wu Z; Lau TC; Lu X; Liu L; Cheung AK; Tan Z; Ng J; Liang J; Wang H; Li S; Zheng B; Li B; Chen L; Chen Z
J Biol Chem; 2012 May; 287(20):16499-509. PubMed ID: 22447925
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention.
Dezzutti CS; Yandura S; Wang L; Moncla B; Teeple EA; Devlin B; Nuttall J; Brown ER; Rohan LC
Pharm Res; 2015 Nov; 32(11):3768-81. PubMed ID: 26078001
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.
Kish-Catalone TM; Lu W; Gallo RC; DeVico AL
Antimicrob Agents Chemother; 2006 Apr; 50(4):1497-509. PubMed ID: 16569870
[TBL] [Abstract][Full Text] [Related]
18. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
Lieberman-Blum SS; Fung HB; Bandres JC
Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
[TBL] [Abstract][Full Text] [Related]
20. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
